Remove Biochemical Assays Remove Regulations Remove Treatment
article thumbnail

The peptide DR3penA exhibits antifibrotic activity in multiple pulmonary fibrosis models induced by particulate and soluble chemical fibrogenic agents [Gastrointestinal, Hepatic, Pulmonary, and Renal]

ASPET

Based on the druggability of DR3penA, we sought to investigate its effects on respirable particulate silicon dioxide (SiO 2 )- and soluble chemical paraquat (PQ)-induced pulmonary fibrosis in this study by using western blot, RT-qPCR, immunofluorescence, H&E and Masson staining, immunohistochemistry and serum biochemical assays.

article thumbnail

Analysis Life Sciences Thank You Amid broader shift on LDT policy, FDA unveils pilot program for cancer drug-linked tests and diagnostics

Agency IQ

This includes treatments or therapeutics that are intended to serve a specific population that can only be selected (or excluded) via diagnostic guidelines, products for which a diagnostic could identify high-risk patients, and/or those that require monitoring for treatment adjustments. For now, LDTs are filling the gap.

FDA 40
article thumbnail

Unique self-activating proteins for drug discovery

Drug Target Review

Å resolution) 6 is now being targeted for small molecule inhibitor discovery and development, by exploiting emergent computational tools to identify potential candidate compounds in silico and then test these predicted inhibitors in in vitro biochemical assays. NIH R01 DA048153 (to D.P.S.), Epub 20230720. doi: 10.1128/jcm.01269-22.